Exploring the Existing Drug Space for Novel pTyr Mimetic and SHP2 Inhibitors

ACS Medicinal Chemistry Letters

Volumn 6, Issue 7, 2015, Pages 782-786

  He, Rongjun ^a   Yu, Zhi Hong ^a   Zhang, Ruo Yu ^a   Wu, Li ^a   Gunawan, Andrea M ^a   Lane, Brandon S ^a   Shim, Joong S ^b   Zeng, Li Fan ^a   He, Yantao ^a   Chen, Lan ^a   Wells, Clark D ^a   Liu, Jun O ^b   Zhang, Zhong Yin ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anticancer agents; fragment based library; Protein tyrosine phosphatase; pTyr mimetics; SHP2 inhibitors

Indexed keywords

CEFSULODIN; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ARTICLE; CANCER CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG DESIGN; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84936861995     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00118     Document Type: Article

References (23)

1. Cohen, P.; Alessi, D. R. Kinase Drug Discovery-What's Next in the Field? ACS Chem. Biol. 2013, 8, 96-104
2. Neel, B. G.; Gu, H. H.; Pao, L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling Trends Biochem. Sci. 2003, 28, 284-293
3. Grossmann, K. S.; Rosario, M.; Birchmeier, C.; Birchmeier, W. The Tyrosine Phosphatase Shp2 in Development and Cancer Adv. Cancer Res. 2010, 106, 53-89
4. Bentires-Alj, M.; Paez, J. G.; David, F. S.; Keilhack, H.; Halmos, B.; Naoki, K.; Maris, J. M.; Richardson, A.; Bardelli, A.; Sugarbaker, D. J.; Richards, W. G.; Du, J. Y.; Girard, L.; Minna, J. D.; Loh, M. L.; Fisher, D. E.; Velculescu, V. E.; Vogelstein, B.; Meyerson, M.; Sellers, W. R.; Neel, B. G. Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia Cancer Res. 2004, 64, 8816-8820
5. Tartaglia, M.; Gelb, B. D. Noonan Syndrome and Related Disorders: Genetics and Pathogenesis. In Annual Review of Genomics and Human Genetics; Annual Reviews: Palo Alto, CA, 2005; Vol. 6, pp 45-68.
6. Butterworth, S.; Overduin, M.; Barr, A. J. Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention Future Med. Chem. 2014, 6, 1423-1437
7. Barr, A. J.; Ugochukwu, E.; Lee, W. H.; King, O. N. F.; Filippakopoulos, P.; Alfano, I.; Savitsky, P.; Burgess-Brown, N. A.; Muller, S.; Knapp, S. Large-scale structural analysis of the classical human protein tyrosine phosphatome Cell 2009, 136, 352-363
8. Puius, Y. A.; Zhao, Y.; Sullivan, M.; Lawrence, D. S.; Almo, S. C.; Zhang, Z. Y. Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: A paradigm for inhibitor design Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 13420-13425
9. Shen, K.; Keng, Y. F.; Wu, L.; Guo, X. L.; Lawrence, D. S.; Zhang, Z. Y. Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure J. Biol. Chem. 2001, 276, 47311-47319
10. He, R. J.; Zeng, L. F.; He, Y. T.; Zhang, S.; Zhang, Z. Y. Small molecule tools for functional interrogation of protein tyrosine phosphatases FEBS J. 2013, 280, 731-750
11. Chong, C. R.; Chen, X. C.; Shi, L. R.; O Liu, J.; Sullivan, D. J. A clinical drug library screen identifies astemizole as an antimalarial agent Nat. Chem. Biol. 2006, 2, 415-416
12. Miller, O. J.; El Harrak, A.; Mangeat, T.; Baret, J. C.; Frenz, L.; El Debs, B.; Mayot, E.; Samuels, M. L.; Rooney, E. K.; Dieu, P.; Galvan, M.; Link, D. R.; Griffiths, A. D. High-resolution dose-response screening using droplet-based microfluidics Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 378-383
13. Sarmiento, M.; Puius, Y. A.; Vetter, S. W.; Keng, Y. F.; Wu, L.; Zhao, Y.; Lawrence, D. S.; Almo, S. C.; Zhang, Z. Y. Structural basis of plasticity in protein tyrosine phosphatase 1B substrate recognition Biochemistry 2000, 39, 8171-8179
14. Xu, J.; Zeng, L. F.; Shen, W. H.; Turchi, J. J.; Zhang, Z. Y. Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma Biochem. Biophys. Res. Commun. 2013, 439, 586-590
15. Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2005, 2, 225-235
16. Ren, Y.; Meng, S.; Mei, L.; Zhao, Z. J.; Jove, R.; Wu, J. Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor J. Biol. Chem. 2004, 279, 8497-8505
17. Yamauchi, K.; Milarski, K. L.; Saltiel, A. R.; Pessin, J. E. Protein-tyrosine-phosphatase SHPTP2 is a required positive effector for insulin downstream signaling Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 664-668
18. Marquardt, B.; Frith, D.; Stabel, S. Signaling from TPA to map kinase requires protein-kinase-c, Raf and MEK-reconstitution of the signaling pathway in-vitro Oncogene 1994, 9, 3213-3218
19. Ueda, Y.; Hirai, S.; Osada, S.; Suzuki, A.; Mizuno, K.; Ohno, S. Protein kinase C delta activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf J. Biol. Chem. 1996, 271, 23512-23519
20. Muthuswamy, S. K.; Xue, B. Cell Polarity as a Regulator of Cancer Cell Behavior Plasticity Annu. Rev. Cell Dev.Biol. 2012, 28, 599-625
21. Weigelt, B.; Lo, A. T.; Park, C. C.; Gray, J. W.; Bissell, M. J. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment Breast Cancer Res. Treat. 2010, 122, 35-43
22. Ashburn, T. T.; Thor, K. B. Drug repositioning: Identifying and developing new uses for existing drugs Nat. Rev. Drug Discovery 2004, 3, 673-683
23. Chong, C. R.; Sullivan, D. J. New uses for old drugs Nature 2007, 448, 645-646